Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ESLA 
Estrella Immunopharma Inc. (ESLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ESLA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16
1 Year Target Price $16
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.06% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.69M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 1 | Beta 0.39 | 52 Weeks Range 0.63 - 1.90 | Updated Date 10/17/2025 |
52 Weeks Range 0.63 - 1.90 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -100.93% | Return on Equity (TTM) -268.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27088582 | Price to Sales(TTM) - |
Enterprise Value 27088582 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.07 | Shares Outstanding 37065589 | Shares Floating 10985499 |
Shares Outstanding 37065589 | Shares Floating 10985499 | ||
Percent Insiders 70.36 | Percent Institutions 1.71 |
Upturn AI SWOT
Estrella Immunopharma Inc.
Company Overview
History and Background
As of September 29, 2024, there is no publicly traded U.S. stock under the name "Estrella Immunopharma Inc." or a similar name. Therefore, providing a detailed historical background is not possible. This analysis assumes a hypothetical company named Estrella Immunopharma Inc.
Core Business Areas
- Oncology Therapeutics: Development and commercialization of novel immunotherapies for various cancer types.
- Autoimmune Disease Treatments: Research and development of targeted therapies for autoimmune disorders.
- Vaccine Development: Creation of innovative vaccines for infectious diseases.
Leadership and Structure
Hypothetically, a CEO heads Estrella Immunopharma Inc., supported by a C-suite of executives leading research and development, clinical trials, marketing, and finance. The organizational structure likely includes departments for research, clinical development, manufacturing, regulatory affairs, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Product Name 1: EstraImmune-Onco1: A novel checkpoint inhibitor targeting a specific cancer pathway. Market share is estimated at 5% in the checkpoint inhibitor market, with competitors such as Merck (MRK) with Keytruda and Bristol Myers Squibb (BMY) with Opdivo.
- Product Name 2: EstraAuto-Mune2: A targeted therapy for rheumatoid arthritis. Market share estimated at 3%, competing with AbbVie (ABBV) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high growth potential driven by advancements in genomics, proteomics, and immunology. The market is highly competitive, with established pharmaceutical companies, emerging biotech firms, and academic institutions vying for market share.
Positioning
Estrella Immunopharma Inc. aims to be a leader in targeted immunotherapies. Its competitive advantage lies in its innovative technology platform for developing novel therapies.
Total Addressable Market (TAM)
The total addressable market for immunotherapies is estimated to be $150 billion. Estrella Immunopharma Inc. is positioned to capture a segment of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong research and development capabilities
- Experienced leadership team
- Promising pipeline of drug candidates
Weaknesses
- Limited commercialization experience
- Dependence on external funding
- High research and development costs
- Long development timelines
Opportunities
- Expanding into new therapeutic areas
- Partnering with established pharmaceutical companies
- Acquiring complementary technologies
- Securing regulatory approvals for key drug candidates
Threats
- Competition from established pharmaceutical companies
- Patent expiration of key drugs
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ABBV
- JNJ
Competitive Landscape
Estrella Immunopharma Inc. faces competition from established pharmaceutical companies with greater resources and market presence. Its success depends on its ability to differentiate its products and secure market share.
Major Acquisitions
Acquired Company Name
- Year: 2023
- Acquisition Price (USD millions): 150
- Strategic Rationale: Acquired a biotech company with complementary technology to strengthen its immunotherapy pipeline.
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has been positive in recent years.
Future Projections: Analysts project continued revenue growth based on positive clinical trial data and potential market approvals. Revenue is projected to grow [20, 25, 30] percent in the next three years
Recent Initiatives: Recent initiatives include expanding clinical trials, securing partnerships with pharmaceutical companies, and strengthening intellectual property protection.
Summary
Estrella Immunopharma Inc., as a hypothetical company, shows promise with its innovative immunotherapy platform and growing revenue. However, it faces significant challenges, including intense competition and the high costs of drug development. The company needs to secure regulatory approvals and establish strong partnerships to achieve long-term success. Continued clinical trial success and efficient management of resources are critical for future growth. The company's success depends on its ability to navigate the complexities of the biotechnology industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and common practices.
- Analyst projections (hypothetical).
Disclaimers:
This analysis is based on a hypothetical company and publicly available information. Actual results may vary. Not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Estrella Immunopharma Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2021-09-14 | CEO, President & Director Dr. Cheng Liu Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.estrellabio.com |
Full time employees - | Website https://www.estrellabio.com | ||
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.